Can’t escape ORAL Surveillance RCT talk Lots of real world data on CV risk & JAKi here (with all the selection, measurement bias) First up: multinational JAK-pot study (n=>50k) Even if you mirror the high-risk RCT cohort - not much there for MACE OP0219 #EULAR2023 @RheumNow https://t.co/FfNspdivri